<DOC>
	<DOCNO>NCT00002942</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy autologous bone marrow transplantation peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Randomized phase III trial compare bone marrow transplantation peripheral stem cell transplantation follow carboplatin treat patient breast cancer .</brief_summary>
	<brief_title>Bone Marrow Peripheral Stem Cell Transplantation Treating Patients With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare engraftment rate use G-CSF prim autologous bone marrow v PBCP hematopoietic support follow high dose CTCb patient poor prognosis breast cancer . II . Compare complication two method hematopoietic progenitor cell collection . III . Compare Stage IV patient bone bone marrow involvement ( assign PBPC collection ) Stage IV patient randomize PBPC collection relative number leukaphereses need collect require number progenitor cell well assess engraftment rate two group . IV . Assess response high dose CTCb group patient . OUTLINE : All patient receive G-CSF prim therapy 5 consecutive day . Patients randomize two treatment arm : Arm 1 consist autologous PBPC collection Arm 2 consist autologous bone marrow collection Within 2 week progenitor cell collection , patient receive high dose CTCb therapy continuous infusion 5 day , follow autologous hematopoietic progenitor cell infusion least three day later . G-CSF also give infusion ANC count 5,000 1,000 3 consecutive day . PROJECTED ACCRUAL : 66 patient accrue rate 24 per year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Stage IIIB IV adenocarcinoma breast Stage IIIIIA adenocarcinoma breast poor risk feature ( include poorly differentiate histology , high mitotic rate , hormone receptor negative , high S phase ) least three involved axillary lymph node , estimate five year relapse free survival rate le 50 % , qualify high priority protocol treatments No central nervous system involvement PATIENT CHARACTERISTICS : Age : 18 60 Performance status : Karnofsky 80100 % Life expectancy : Greater 2 month Hematopoietic : Platelet count great 75,000/mm3 Neutrophils great 1500/mm3 Hepatic : Serum bilirubin , alkaline phosphatase , SGOT SGPT less 3 time upper limit normal , unless due disease Renal : Serum creatinine less 1.5 time upper limit normal Creatinine clearance least 60 mL.min Cardiovascular : Ventricular ejection fraction least 45 % No uncontrolled severe cardiovascular disease , include recent myocardial infarction , congestive heart failure , angina , life threaten arrhythmia , hypertension Pulmonary : DLCO spirometry least 50 % predict Other : Not HIV positive Not HBsAG positive Not pregnant Must function central venous catheter No active infection No uncontrolled diabetes mellitus No prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated Stage I II cancer patient currently complete remission , cancer patient disease free least 5 year PRIOR CONCURRENT THERAPY : Biologic therapy : No prior hematopoietic progenitor cell support Chemotherapy : No prior dose intensive therapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>